Simulations Plus, Inc. (NASDAQ:SLP) was the target of a large increase in short interest during the month of August. As of August 15th, there was short interest totalling 330,100 shares, an increase of 27.6% from the July 15th total of 258,800 shares. Based on an average daily trading volume, of 134,800 shares, the days-to-cover ratio is currently 2.4 days. Currently, 2.7% of the company’s stock are sold short.
NASDAQ:SLP traded down $0.64 during trading hours on Tuesday, reaching $36.00. The company had a trading volume of 100,110 shares, compared to its average volume of 88,761. The stock has a 50-day moving average of $36.00 and a two-hundred day moving average of $26.36. Simulations Plus has a one year low of $17.18 and a one year high of $41.95. The firm has a market capitalization of $640.02 million, a PE ratio of 72.00 and a beta of -0.35.
Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Wednesday, July 10th. The technology company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02. Simulations Plus had a return on equity of 23.48% and a net margin of 24.09%. The firm had revenue of $9.94 million for the quarter, compared to analysts’ expectations of $9.85 million. As a group, equities research analysts predict that Simulations Plus will post 0.46 earnings per share for the current year.
A number of research firms have recently issued reports on SLP. Zacks Investment Research upgraded Simulations Plus from a “hold” rating to a “strong-buy” rating and set a $37.00 price objective on the stock in a research report on Friday, July 19th. ValuEngine cut Simulations Plus from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 2nd. Finally, BidaskClub upgraded Simulations Plus from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 15th.
In other news, Director John Kenneth Paglia sold 690 shares of Simulations Plus stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $37.86, for a total transaction of $26,123.40. Following the completion of the sale, the director now directly owns 2,112 shares in the company, valued at approximately $79,960.32. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 31.57% of the stock is owned by insiders.
Institutional investors have recently bought and sold shares of the business. BNP Paribas Arbitrage SA boosted its stake in Simulations Plus by 59,875.0% in the first quarter. BNP Paribas Arbitrage SA now owns 2,399 shares of the technology company’s stock worth $51,000 after purchasing an additional 2,395 shares in the last quarter. Neuburgh Advisers LLC lifted its stake in shares of Simulations Plus by 419.4% during the second quarter. Neuburgh Advisers LLC now owns 2,576 shares of the technology company’s stock valued at $74,000 after acquiring an additional 2,080 shares during the period. Glen Harbor Capital Management LLC lifted its stake in shares of Simulations Plus by 419.4% during the second quarter. Glen Harbor Capital Management LLC now owns 3,542 shares of the technology company’s stock valued at $101,000 after acquiring an additional 2,860 shares during the period. MetLife Investment Advisors LLC acquired a new position in shares of Simulations Plus during the fourth quarter valued at $108,000. Finally, Elkfork Partners LLC lifted its stake in shares of Simulations Plus by 419.4% during the second quarter. Elkfork Partners LLC now owns 4,508 shares of the technology company’s stock valued at $129,000 after acquiring an additional 3,640 shares during the period. 41.48% of the stock is currently owned by institutional investors.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Further Reading: How to read a candlestick chart
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.